
## Basilia Zingarelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7253819/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	First Do No Harm: A Proposal of an Expert-Guided Framework of Surrogate Humane Endpoints in Preclinical Models of Acute Lung Injury*. Critical Care Medicine, 2021, 49, 373-375.	0.4	1
2	Administration of GDF3 Into Septic Mice Improves Survival via Enhancing LXRα-Mediated Macrophage Phagocytosis. Frontiers in Immunology, 2021, 12, 647070.	2.2	9
3	Deficiency of AMPKα1 Exacerbates Intestinal Injury and Remote Acute Lung Injury in Mesenteric Ischemia and Reperfusion in Mice. International Journal of Molecular Sciences, 2021, 22, 9911.	1.8	8
4	AC6 regulates the microtubule-depolymerizing kinesin KIF19A to control ciliary length in mammals. Journal of Biological Chemistry, 2020, 295, 14250-14259.	1.6	13
5	Intrathoracic Pressure Regulator Performance in the Setting of Hemorrhage and Acute Lung Injury. Military Medicine, 2020, 185, e1083-e1090.	0.4	2
6	Hepatocyte-Specific Deletion of AMPKα1 Results in Worse Outcomes in Mice Subjected to Sepsis in a Sex-Specific Manner. Frontiers in Immunology, 2020, 11, 210.	2.2	13
7	miR-145a Regulation of Pericyte Dysfunction in a Murine Model of Sepsis. Journal of Infectious Diseases, 2020, 222, 1037-1045.	1.9	9
8	Age-Dependent Myocardial Dysfunction in Critically Ill Patients: Role of Mitochondrial Dysfunction. International Journal of Molecular Sciences, 2019, 20, 3523.	1.8	3
9	The olfactomedin-4 positive neutrophil has a role in murine intestinal ischemia/reperfusion injury. FASEB Journal, 2019, 33, 13660-13668.	0.2	9
10	Reply to Angé et al American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H936-H937.	1.5	0
11	Part I: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Study Design and Humane Modeling Endpoints. Shock, 2019, 51, 10-22.	1.0	57
12	Exosomes from endothelial progenitor cells improve outcomes of the lipopolysaccharide-induced acute lung injury. Critical Care, 2019, 23, 44.	2.5	183
13	The Response to the Letter to the Editor Titled: "ls Triple Self-plagiarism "OKâ€If Only Made Transparent?―by Volker R Jacobs, MD, MBA. Shock, 2019, 51, 140-141.	1.0	0
14	1822. Critical Care Medicine, 2019, 47, 884.	0.4	0
15	Humanin Improves Lung Inflammation During Hemorrhagic Shock. Journal of the American College of Surgeons, 2019, 229, S297.	0.2	0
16	Activation of AMP-Activated Protein Kinase by A769662 Ameliorates Sepsis-Induced Acute Lung Injury in Adult Mice. Shock, 2019, 52, 540-549.	1.0	18
17	1817. Critical Care Medicine, 2019, 47, 882.	0.4	0
18	Sepsis Induces Adipose Tissue Browning in Nonobese Mice But Not in Obese Mice. Shock, 2018, 50, 557-564.	1.0	14

#	Article	IF	CITATIONS
19	Autophagy and mitochondrial biogenesis impairment contribute to ageâ€dependent liver injury in experimental sepsis: dysregulation of AMPâ€activated protein kinase pathway. FASEB Journal, 2018, 32, 728-741.	0.2	43
20	Metformin Exerts Beneficial Effects in Hemorrhagic Shock in An AMPKα1-Independent Manner. Shock, 2018, 49, 277-287.	1.0	7
21	Genetic Deficiency of AMPKα1 Exacerbates Intestinal Barrier Dysfunction in Mesenteric Ischemia/Reperfusion Injury in Mice. Journal of the American College of Surgeons, 2018, 227, S80.	0.2	Ο
22	Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): An International Expert Consensus Initiative for Improvement of Animal Modeling in Sepsis. Shock, 2018, 50, 377-380.	1.0	141
23	Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial. Intensive Care Medicine, 2018, 44, 2006-2008.	3.9	5
24	Age-dependent cardiac function during experimental sepsis: effect of pharmacological activation of AMP-activated protein kinase by AICAR. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H826-H837.	1.5	19
25	Fli-1 Governs Pericyte Dysfunction in a Murine Model of Sepsis. Journal of Infectious Diseases, 2018, 218, 1995-2005.	1.9	23
26	Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. Infection, 2018, 46, 687-691.	2.3	28
27	Minimum quality threshold in pre-clinical sepsis studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. Intensive Care Medicine Experimental, 2018, 6, 26.	0.9	61
28	Age-Dependent Changes in AMPK Metabolic Pathways in the Lung in a Mouse Model of Hemorrhagic Shock. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 585-596.	1.4	20
29	The AMPK Activator Aicar Ameliorates Age-Dependent Myocardial Injury in Murine Hemorrhagic Shock. Shock, 2017, 47, 70-78.	1.0	11
30	What's New in Shock, May 2017?. Shock, 2017, 47, 533-536.	1.0	1
31	Metformin ameliorates gender-and age-dependent hemodynamic instability and myocardial injury in murine hemorrhagic shock. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 2680-2691.	1.8	23
32	Intestine-Derived Matrix Metalloproteinase-8 Is a Critical Mediator of Polymicrobial Peritonitis*. Critical Care Medicine, 2016, 44, e200-e206.	0.4	15
33	Matrix Metalloproteinase-8 Augments Bacterial Clearance in a Juvenile sepsis Model. Molecular Medicine, 2016, 22, 455-463.	1.9	15
34	A Stromal Cell-Derived Factor 1α Analogue Improves Endothelial Cell Function in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome. Molecular Medicine, 2016, 22, 115-123.	1.9	17
35	Obesity enhances sepsisâ€induced liver inflammation and injury in mice. Obesity, 2016, 24, 1480-1488.	1.5	26
36	Role of matrix metalloproteinaseâ€8 as a mediator of injury in intestinal ischemia and reperfusion. FASEB Journal, 2016, 30, 3453-3460.	0.2	15

#	Article	IF	CITATIONS
37	Exosomal miR-223 Contributes to Mesenchymal Stem Cell-Elicited Cardioprotection in Polymicrobial Sepsis. Scientific Reports, 2015, 5, 13721.	1.6	242
38	Age-dependent therapeutic effects of liver X receptor-α activation in murine polymicrobial sepsis. Innate Immunity, 2015, 21, 609-618.	1.1	9
39	Blockade of exosome generation with GW4869 dampens the sepsis-induced inflammation and cardiac dysfunction. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2362-2371.	1.8	307
40	Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis. Innate Immunity, 2014, 20, 519-528.	1.1	64
41	Conditional Deletion of Cardiomyocyte Peroxisome Proliferator-Activated Receptor γ Enhances Myocardial Ischemia-Reperfusion Injury in Mice. Shock, 2014, 41, 40-47.	1.0	14
42	Combined Zinc Supplementation With Proinsulin C-Peptide Treatment Decreases the Inflammatory Response and Mortality in Murine Polymicrobial Sepsis. Shock, 2014, 41, 292-300.	1.0	13
43	Ischemia-Reperfusion Injury. , 2014, , 251-268.		3
44	Loss of duplexmiR-223 (5p and 3p) aggravates myocardial depression and mortality in polymicrobial sepsis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 701-711.	1.8	71
45	Endothelial Progenitor Cells and a Stromal Cell–derived Factor-1α Analogue Synergistically Improve Survival in Sepsis. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1509-1519.	2.5	71
46	940. Critical Care Medicine, 2014, 42, A1586-A1587.	0.4	0
47	961. Critical Care Medicine, 2014, 42, A1591-A1592.	0.4	Ο
48	A novel role for matrix metalloproteinase-8 in sepsis*. Critical Care Medicine, 2012, 40, 379-387.	0.4	80
49	Reduced Peroxisome Proliferator-Activated Receptor α Expression Is Associated With Decreased Survival and Increased Tissue Bacterial Load in Sepsis. Shock, 2012, 37, 164-169.	1.0	68
50	Toll-like Receptor-Induced Inflammatory Cytokines are Suppressed by Gain of Function or Overexpression of $Gl^{\pm}$ i2 Protein. Inflammation, 2012, 35, 1611-1617.	1.7	16
51	Shortâ€Term High Fat Feeding Increases Organ Injury and Mortality After Polymicrobial Sepsis. Obesity, 2012, 20, 1995-2002.	1.5	38
52	Liver X Receptor α Activation with the Synthetic Ligand T0901317 Reduces Lung Injury and Inflammation After Hemorrhage and Resuscitation Via Inhibition of the Nuclear Factor κB Pathway. Shock, 2011, 35, 367-374.	1.0	25
53	Small interfering RNA mediated Poly (ADP-ribose) Polymerase-1 inhibition upregulates the heat shock response in a murine fibroblast cell line. Journal of Inflammation, 2011, 8, 3.	1.5	1
54	What's Now in SHOCK March 20112 Check 2011 25 217 210	1.0	

54 What's New in SHOCK, March 2011?. Shock, 2011, 35, 217-219.

1.0 0

#	Article	IF	CITATIONS
55	C-peptide, a novel inhibitor of lung inflammation following hemorrhagic shock. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L730-L739.	1.3	25
56	hildren are not Small Adults!". The Open Inflammation Journal, 2011, 4, 4-15.	0.5	58
57	Novel Therapeutic Agents in Pediatric Sepsis: Peroxisome Proliferator Receptor γ (PPAR γ) Agonists. The Open Inflammation Journal, 2011, 4, 120-124.	0.5	9
58	Toll-like receptor-2 and disturbances of the cardiac rhythm: Life changes in a heartbeat*. Critical Care Medicine, 2010, 38, 2062-2063.	0.4	0
59	Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock. Intensive Care Medicine, 2010, 36, 123-130.	3.9	37
60	Betaâ€arrestin 2 negatively regulates sepsisâ€induced inflammation. Immunology, 2010, 130, 344-351.	2.0	65
61	Phosphorylation of Extracellular Signal-Regulated Kinase (ERK)-1/2 Is Associated with the Downregulation of Peroxisome Proliferator-Activated Receptor (PPAR)-γ during Polymicrobial Sepsis. Molecular Medicine, 2010, 16, 491-497.	1.9	31
62	Liver apoptosis is age dependent and is reduced by activation of peroxisome proliferator-activated receptor-I <sup>3</sup> in hemorrhagic shock. American Journal of Physiology - Renal Physiology, 2010, 298, G133-G141.	1.6	12
63	Peroxisome Proliferator-Activated Receptor δ Regulates Inflammation via NF-κB Signaling in Polymicrobial Sepsis. American Journal of Pathology, 2010, 177, 1834-1847.	1.9	65
64	Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock. International Journal of Clinical and Experimental Medicine, 2010, 3, 1-9.	1.3	5
65	Overexpression of Hsp20 prevents endotoxin-induced myocardial dysfunction and apoptosis via inhibition of NF-κB activation. Journal of Molecular and Cellular Cardiology, 2009, 47, 382-390.	0.9	59
66	Lung injury after hemorrhage is age dependent: Role of peroxisome proliferator-activated receptor γ*. Critical Care Medicine, 2009, 37, 1978-1987.	0.4	52
67	Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response. Recent Patents on Inflammation and Allergy Drug Discovery, 2009, 3, 96-112.	3.9	50
68	Ischemia-Reperfusion Injury. , 2009, , 1-12.		1
69	Peroxisome proliferator-activated receptor-γ protects against hepatic ischemia/reperfusion injury in mice. Hepatology, 2008, 47, 215-224.	3.6	70
70	Peroxisome proliferator activated receptor Î <sup>3</sup> is not necessary for the development of LPS-induced tolerance in macrophages. Immunology, 2008, 124, 51-57.	2.0	3
71	Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. European Journal of Pharmacology, 2008, 579, 411-417.	1.7	90
72	Caspases inhibition decreases neurological sequelae in meningitis*. Critical Care Medicine, 2008, 36, 1603-1606.	0.4	52

#	Article	IF	CITATIONS
73	Ciglitazone ameliorates lung inflammation by modulating the inhibitor κB protein kinase/nuclear factor-κB pathway after hemorrhagic shock. Critical Care Medicine, 2008, 36, 2849-2857.	0.4	47
74	Lysophosphatidic Acid Inhibits Bacterial Endotoxin-Induced Pro-Inflammatory Response: Potential Anti-Inflammatory Signaling Pathways. Molecular Medicine, 2008, 14, 422-428.	1.9	42
75	INDUCTION OF ENDOTOXIN TOLERANCE ENHANCES BACTERIAL CLEARANCE AND SURVIVAL IN MURINE POLYMICROBIAL SEPSIS. Shock, 2008, 30, 267-273.	1.0	101
76	beta-Arrestin 2: a Negative Regulator of Inflammatory Responses in Polymorphonuclear Leukocytes. International Journal of Clinical and Experimental Medicine, 2008, 1, 32-41.	1.3	27
77	THE GREEN TEA POLYPHENOL EPIGALLOCATECHIN-3-GALLATE IMPROVES SYSTEMIC HEMODYNAMICS AND SURVIVAL IN RODENT MODELS OF POLYMICROBIAL SEPSIS. Shock, 2007, 28, 353-359.	1.0	42
78	Proinsulin c-peptide exerts beneficial effects in endotoxic shock in mice. Critical Care Medicine, 2007, 35, 1348-1355.	0.4	37
79	Surfactant treatment of neonatal acute respiratory distress syndrome: Is "fortification―the answer?*. Critical Care Medicine, 2007, 35, 2442-2443.	0.4	1
80	DIVERSE CARDIOPROTECTIVE SIGNALING MECHANISMS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Î <sup>3</sup> LIGANDS, 15-DEOXY-Δ12,14-PROSTAGLANDIN J2 AND CIGLITAZONE, IN REPERFUSION INJURY. Shoc 2007, 28, 554-563.	k1.0	56
81	Differential regulation of lipopolysaccharide and Gram-positive bacteria induced cytokine and chemokine production in macrophages by G?iproteins. Immunology, 2007, 122, 116-123.	2.0	23
82	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR Î <sup>3</sup> IS REQUIRED FOR THE INHIBITORY EFFECT OF CIGLITAZONE BUT NOT 15-DEOXY-Δ12,14-PROSTAGLANDIN J2 ON THE NFκB PATHWAY IN HUMAN ENDOTHELIAI CELLS. Shock, 2007, 28, 722-726.	L1.0	24
83	Erythropoietin: A role in intensive care beyond erythropoiesis?*. Critical Care Medicine, 2006, 34, 1281-1282.	0.4	0
84	SYNERGISTIC EFFECT OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-Î <sup>3</sup> AND LIVER X RECEPTOR-α IN THE REGULATION OF INFLAMMATION IN MACROPHAGES. Shock, 2006, 26, 146-153.	1.0	32
85	THE PHOSPHATIDYLINOSITOL 3 KINASE PATHWAY REGULATES TOLERANCE TO LIPOPOLYSACCHARIDE AND PRIMING RESPONSES TO STAPHYLOCOCCUS AUREUS AND LIPOPOLYSACCHARIDE. Shock, 2006, 26, 31-36.	1.0	7
86	Gi proteins regulate lipopolysaccharide and Staphylococcus aureus induced cytokine production but not (1(r) 3)-beta-D-glucan induced cytokine suppression. Frontiers in Bioscience - Landmark, 2006, 11, 2264.	3.0	7
87	Nuclear factor-κB. Critical Care Medicine, 2005, 33, S414-S416.	0.4	80
88	AGE-DEPENDENT RESPONSES TO HEPATIC ISCHEMIA/REPERFUSION INJURY. Shock, 2005, 24, 421-427.	1.0	81
89	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-?? IS A NEW THERAPEUTIC TARGET IN SEPSIS AND INFLAMMATION. Shock, 2005, 23, 393-399.	1.0	137
90	15-DEOXY-??12,14-PROSTAGLANDIN J2 (15D-PGJ2), A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ?? LIGAND, REDUCES TISSUE LEUKOSEQUESTRATION AND MORTALITY IN ENDOTOXIC SHOCK. Shock, 2005, 24, 59-65.	1.0	85

#	Article	IF	CITATIONS
91	Calpain inhibition decreases endothelin-1 levels and pulmonary hypertension after cardiopulmonary bypass with deep hypothermic circulatory arrest*. Critical Care Medicine, 2005, 33, 623-628.	0.4	41
92	Dexamethasone decreases neurological sequelae and caspase activity. Intensive Care Medicine, 2005, 31, 146-150.	3.9	35
93	Inhibitors of poly (ADP-ribose) polymerase ameliorate myocardial reperfusion injury by modulation of activator protein-1 and neutrophil infiltration. Shock, 2005, 23, 233-8.	1.0	10
94	Epigallocatechin, a Green Tea Polyphenol, Attenuates Myocardial Ischemia Reperfusion Injury in Rats. Molecular Medicine, 2004, 10, 55-62.	1.9	173
95	Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H1408-H1415.	1.5	65
96	Activator protein-1 signalling pathway and apoptosis are modulated by poly(ADP-ribose) polymerase-1 in experimental colitis. Immunology, 2004, 113, 509-517.	2.0	63
97	15-DEOXY-Δ12,14-PROSTAGLANDIN J2 (15D-PGJ2), A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMI (PPARÎ <sup>3</sup> ) LIGAND, REDUCES TISSUE LEUKOSEQUESTRATION AND MORTALITY IN ENDOTOXIC SHOCK Shock, 2004, 21, 32.	MA 1.0	2
98	Peptidoglycan is an important pathogenic factor of the inflammatory response in sepsis *. Critical Care Medicine, 2004, 32, 613-614.	0.4	5
99	Ethyl pyruvate: A simple solution?*. Critical Care Medicine, 2004, 32, 1603-1604.	0.4	10
100	TEA FLAVANOIDS INHIBIT NOS2 EXPRESSION AND ACTIVITY IN VIVO AND IN VITRO. Critical Care Medicine, 2004, 32, A129.	0.4	0
101	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) IS REQUIRED FOR THE INHIBITORY EFFECT OF CIGLITAZONE BUT NOT 15-DEOXY-12,14-PROSTAGLANDIN J2 (15D-PGJ2) ON THE NF-B PATHWAY IN HUMAN ENDOTHELIAL CELLS. Critical Care Medicine, 2004, 32, A18.	0.4	Ο
102	Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways in colitis. European Journal of Pharmacology, 2003, 469, 183-194.	1.7	45
103	Poly(ADP-Ribose) Polymerase-1 Regulates Activation of Activator Protein-1 in Murine Fibroblasts. Journal of Immunology, 2003, 170, 2113-2120.	0.4	104
104	Peroxisome Proliferator Activator Receptor-γ Ligands, 15-Deoxy-Δ12,14-Prostaglandin J2 and Ciglitazone, Reduce Systemic Inflammation in Polymicrobial Sepsis by Modulation of Signal Transduction Pathways. Journal of Immunology, 2003, 171, 6827-6837.	0.4	198
105	Inhibition of Nitric Oxide Restores Surfactant Gene Expression following Nickel-Induced Acute Lung Injury. American Journal of Respiratory Cell and Molecular Biology, 2003, 28, 188-198.	1.4	24
106	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AGONISTS MODULATE MACROPHAGE ACTIVATION BY GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIAL STIMULI. Shock, 2003, 20, 56-62.	1.0	37
107	Nuclear factor-κB as a therapeutic target in critical care medicine. Critical Care Medicine, 2003, 31, S105-S111.	0.4	170
108	Parthenolide improves systemic hemodynamics and decreases tissue leukosequestration in rats with polymicrobial sepsis*. Critical Care Medicine, 2003, 31, 2263-2270.	0.4	62

#	Article	IF	CITATIONS
109	Absence of Poly(ADP-ribose) Polymerase-1 Alters Nuclear Factor-κB Activation and Gene Expression of Apoptosis Regulators after Reperfusion Injury. Molecular Medicine, 2003, 9, 143-153.	1.9	53
110	Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury. Molecular Medicine, 2003, 9, 1.	1.9	39
111	Parthenolide, an Inhibitor of the Nuclear Factor-κB Pathway, Ameliorates Cardiovascular Derangement and Outcome in Endotoxic Shock in Rodents. Molecular Pharmacology, 2002, 61, 953-963.	1.0	104
112	Absence of inducible nitric oxide synthase modulates early reperfusionâ€induced NFâ€î®B and APâ€1 activation and enhances myocardial damage. FASEB Journal, 2002, 16, 327-342.	0.2	115
113	Inducible Nitric Oxide Synthase Is Not Required in the Development of Endotoxin Tolerance in Mice. Shock, 2002, 17, 478-484.	1.0	23
114	Modulation of nuclear factor-κB activation and decreased markers of neurological injury associated with hypothermic therapy in experimental bacterial meningitis. Critical Care Medicine, 2002, 30, 2553-2559.	0.4	47
115	Sesquiterpene Lactone Parthenolide, an Inhibitor of I??B Kinase Complex and Nuclear Factor-??B, Exerts Beneficial Effects in Myocardial Reperfusion Injury. Shock, 2002, 17, 127-134.	1.0	59
116	EFFECT OF GENETIC DISRUPTION OF POLY (ADP-RIBOSE) SYNTHETASE ON DELAYED PRODUCTION OF INFLAMMATORY MEDIATORS AND DELAYED NECROSIS DURING MYOCARDIAL ISCHEMIA-REPERFUSION INJURY. Shock, 2000, 13, 60-66.	1.0	80
117	Hypothermia as an adjunctive treatment for severe bacterial meningitis. Brain Research, 2000, 881, 88-97.	1.1	65
118	Crucial Role of Endogenous Interleukin-10 Production in Myocardial Ischemia/Reperfusion Injury. Circulation, 2000, 101, 1019-1026.	1.6	272
119	Soluble Nitric Oxide Donor and Surfactant Improve Oxygenation and Pulmonary Hypertension in Porcine Lung Injury. Nitric Oxide - Biology and Chemistry, 2000, 4, 412-422.	1.2	21
120	Mercaptoethylguanidine attenuates inflamation in bacterial meningitis in rabbits. Life Sciences, 2000, 67, 365-372.	2.0	12
121	Protective Effect of 3-Aminobenzamide, an Inhibitor of Poly (ADP-Ribose) Synthetase, against Laryngeal Injury in Rats. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1743-1749.	2.5	17
122	Protective effects of Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic, in paw oedema induced by carrageenan in the rat. Biochemical Pharmacology, 1999, 58, 171-176.	2.0	31
123	Beneficial effects of Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic, in carrageenan-induced pleurisy. Free Radical Biology and Medicine, 1999, 26, 25-33.	1.3	68
124	Protective effects of poly (ADP-ribose) synthase inhibitors in zymosan-activated plasma induced paw edema. Life Sciences, 1999, 65, 957-964.	2.0	19
125	Blockade of poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology, 1999, 116, 335-345.	0.6	141
126	Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat. Critical Care Medicine, 1999, 27, 1517-1523.	0.4	43

#	Article	IF	CITATIONS
127	Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shock. Critical Care Medicine, 1999, 27, 1701-1707.	0.4	48
128	POLY (ADP RIBOSE) SYNTHETASE ACTIVATION OF C-FOS AND C-JUN. Critical Care Medicine, 1999, 27, A95.	0.4	0
129	Effect of L -buthionine-(S,R)-sulphoximine, an inhibitor of γ-glutamylcysteine synthetase on peroxynitrite- and endotoxic shock-induced vascular failure. British Journal of Pharmacology, 1998, 123, 525-537.	2.7	81
130	Protective effect of melatonin in a non-septic shock model induced by zymosan in the rat. Journal of Pineal Research, 1998, 25, 24-33.	3.4	64
131	Antiinflammatory Effects of Mercaptoethylguanidine, a Combined Inhibitor of Nitric Oxide Synthase and Peroxynitrite Scavenger, in Carrageenan-induced Models of Inflammation. Free Radical Biology and Medicine, 1998, 24, 450-459.	1.3	203
132	Evidence for in vivo peroxynitrite production in human chronic hepatitis. Life Sciences, 1998, 63, PL25-PL30.	2.0	29
133	Role of constitutive nitric oxide synthase and peroxynitrite production in a rat model of splanchnic artery occlusion shock. Life Sciences, 1998, 63, 789-799.	2.0	49
134	Role of peroxynitrite and poly (ADP-ribosyl) synthetase activation in cardiovascular derangement induced by zymosan in the rat. Life Sciences, 1998, 63, 923-933.	2.0	26
135	Genetic Disruption of Poly (ADP-Ribose) Synthetase Inhibits the Expression of P-Selectin and Intercellular Adhesion Molecule-1 in Myocardial Ischemia/Reperfusion Injury. Circulation Research, 1998, 83, 85-94.	2.0	326
136	Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFIºB activation. FASEB Journal, 1998, 12, 685-693.	0.2	252
137	EFFECT OF 3-AMINOBENZAMIDE, AN INHIBITOR OF POLY (ADP-RIBOSE) SYNTHETASE, ON THE EXPRESSION OF P-SELECTIN AND INTERCELLULAR ADHESION MOLECULE-1 IN MYOCARDIAL ISCHEMIA-REPERFUSION. Critical Care Medicine, 1998, 26, 35A.	0.4	0
138	PHARMACOLOGICAL INHIBITION, OR GENETIC ABLATION OF POLY (ADP-RIBOSE) SYNTHETASE EXERTS ANTI-INFLAMMATORY EFFECTS IN A ZYMOSAN INDUCED MODEL OF MULTIPLE ORGAN FAILURE. Critical Care Medicine, 1998, 26, 76A.	0.4	0
139	Mercaptoethylguanidine and Guanidine Inhibitors of Nitric-oxide Synthase React with Peroxynitrite and Protect against Peroxynitrite-induced Oxidative Damage. Journal of Biological Chemistry, 1997, 272, 9030-9036.	1.6	153
140	Inhibition of poly (ADP-ribose) Synthetase Attenuates Neutrophil Recruitment and Exerts Antiinflammatory Effects. Journal of Experimental Medicine, 1997, 186, 1041-1049.	4.2	277
141	POLY (ADP-RIBOSE) SYNTHETASE ACTIVATION INDUCED BY PEROXYNITRITE MEDIATES MYOCARDIAL ISCHEMIA AND REPERFUSION INJURY. Shock, 1997, 7, 89.	1.0	2
142	Inhibition of nitric oxide synthase with pyrazole-1-carboxamidine and related compounds. Biochemical Pharmacology, 1997, 54, 409-417.	2.0	21
143	Amelioration by mercaptoethylguanidine of the vascular and energetic failure in haemorrhagic shock in the anesthetised rat. European Journal of Pharmacology, 1997, 338, 55-65.	1.7	45
144	Protection by Inhibition of Poly (ADP-ribose) Synthetase Against Oxidant Injury in Cardiac MyoblastsIn Vitro. Journal of Molecular and Cellular Cardiology, 1997, 29, 2585-2597.	0.9	79

#	Article	IF	CITATIONS
145	Melatonin is a scavenger of peroxynitrite. Life Sciences, 1997, 60, PL169-PL174.	2.0	271
146	Protective effect of melatonin in carrageenan-induced models of local inflammation: Relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. Journal of Pineal Research, 1997, 23, 106-116.	3.4	245
147	The potential role of peroxynitrite in the vascular contractile and cellular energetic failure in endotoxic shock. British Journal of Pharmacology, 1997, 120, 259-267.	2.7	211
148	The inhibitory effects of mercaptoalkylguanidines on cyclo-oxygenase activity. British Journal of Pharmacology, 1997, 120, 357-366.	2.7	58
149	Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. British Journal of Pharmacology, 1997, 121, 1065-1074.	2.7	156
150	Role of peroxynitrite and activation of poly (ADP-ribose) synthetase in the vascular failure induced by zymosan-activated plasma. British Journal of Pharmacology, 1997, 122, 493-503.	2.7	40
151	Spontaneous rearrangement of aminoalkylisothioureas into mercaptoalkylguanidines, a novel class of nitric oxide synthase inhibitors with selectivity towards the inducible isoform. British Journal of Pharmacology, 1996, 117, 619-632.	2.7	71
152	Pharmacological characterization of guanidinoethyldisulphide (GED), a novel inhibitor of nitric oxide synthase with selectivity towards the inducible isoform. British Journal of Pharmacology, 1996, 118, 1659-1668.	2.7	54
153	PROTECTIVE EFFECTS OF NICOTINAMIDE AGAINST NITRIC OXIDE-MEDIATED DELAYED VASCULAR FAILURE IN ENDOTOXIC SHOCK. Shock, 1996, 5, 258-264.	1.0	56
154	LOW-LEVEL EXPRESSION AND LIMITED ROLE FOR THE INDUCIBLE ISOFORM OF NITRIC OXIDE SYNTHASE IN THE VASCULAR HYPOREACTIVITY AND MORTALITY ASSOCIATED WITH CECAL LIGATION AND PUNCTURE IN THE RAT. Shock, 1996, 6, 248-253.	1.0	33
155	Role of Poly-ADP Ribosyltransferase Activation in the Vascular Contractile and Energetic Failure Elicited by Exogenous and Endogenous Nitric Oxide and Peroxynitrite. Circulation Research, 1996, 78, 1051-1063.	2.0	223
156	INCREASED NITRIC OXIDE SYNTHESIS DURING THE DEVELOPMENT OF ENDOTOXIN TOLERANCE. Shock, 1995, 3, 102-108.	1.0	69
157	TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. Agents and Actions, 1994, 42, 128-134.	0.7	9
158	Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock. British Journal of Pharmacology, 1994, 113, 1153-1158.	2.7	33
159	Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents and Actions, 1993, 39, 150-156.	0.7	64
160	The effect of cloricromene, a coumarine derivative, on leukocyte accumulation, myocardial necrosis and TNF-α production in myocardial ischaemia-reperfusion injury. Life Sciences, 1993, 53, 341-355.	2.0	22
161	G 619, a Dual Thromboxane Synthase Inhibitor and Thromboxane A <sub>2</sub> Receptor Antagonist, Reduces Myocardial Damage and Polymorpho-nuclear Leukocyte Accumulation following Coronary Artery Occlusion and Reperfusion in Rats. Pharmacology, 1993, 47, 167-175.	0.9	8
162	Protective Effects of G 619, a Dual Thromboxane Synthase Inhibitor and Thromboxane A2 Receptor Antagonist, in Splanchnic Artery Occlusion Shock. Journal of Cardiovascular Pharmacology, 1992, 19, 115-119.	0.8	14

#	Article	IF	CITATIONS
163	Evidence for a Role of Nitric Oxide in Hypovolemic Hemorrhagic Shock. Journal of Cardiovascular Pharmacology, 1992, 19, 982-986.	0.8	67
164	Cloricromene antagonizes antidipsogenic effects induced by endotoxin, but not by TNFα, in the rat. Life Sciences, 1992, 51, 2041-2048.	2.0	7
165	Cloricromene. Cardiovascular Drug Reviews, 1991, 9, 357-371.	4.4	16